Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications
Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT.
Journal: American journal of preventive cardiology
Published: November 02, 2025
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.
Journal: Atherosclerosis
Published: October 16, 2025
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT.
Journal: European journal of preventive cardiology
Published: October 11, 2025
Long-term amyloid PET and MRI outcomes in a menopausal hormone therapy trial.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 17, 2025
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM.
Journal: American journal of preventive cardiology
Published: September 11, 2025
Correction to: Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Journal: Circulation
Published: July 07, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.
Journal: European journal of preventive cardiology
Published: May 29, 2025
Corrigendum to "Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA" [Atherosclerosis (2025) 403 119114].
Journal: Atherosclerosis
Published: May 02, 2025
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants.
Journal: Drug safety
Published: March 31, 2025
Association between central adiposity and cognitive domain function in recently postmenopausal women: an analysis from the KEEPS-Cog substudy of the Kronos Early Estrogen Preventive Study.
Journal: Menopause (New York, N.Y.)
Published: March 11, 2025
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Journal: Journal of the American Heart Association
Published: February 19, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 31, 2025
Last Updated: 09/26/2026